Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BGS649 · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| BGS649 | DRUG | Capsules will be taken weekly for a maximum of 24 weeks |
| Placebo | DRUG | Capsules were taken weekly for a maximum of 24 weeks |
BGS649 is an investigational small molecule being developed for the treatment of hypogonadotropic hypogonadism, a condition characterized by low testosterone due to inadequate gonadotropin secretion. It is currently in Phase 2 clinical development and has been studied in male obese subjects with this condition.
BGS649 is being developed by Mereo BioPharma Group plc, a biopharmaceutical company listed on the NASDAQ under the ticker symbol MREO. The company is conducting clinical trials to evaluate the safety and efficacy of BGS649 in patients with hypogonadotropic hypogonadism.
BGS649 is in Phase 2 clinical development. Two Phase 2 trials have been completed, with a total enrollment of 414 participants. The drug is investigational and has not been approved by regulatory authorities.
BGS649 has been studied in two completed Phase 2 trials. The first, NCT02730169, evaluated safety and efficacy in 271 male obese subjects with hypogonadotropic hypogonadism. The second, NCT02908074, was a 6-month safety extension study involving 143 participants.
Yes, BGS649 is a small molecule therapeutic. It is being developed as an oral treatment for hypogonadotropic hypogonadism, an endocrine disorder. The drug is currently in Phase 2 clinical trials, with two studies completed.